Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Probing for growth

Probing for growth

Company 2Q EPS est 2Q EPS actual Outcome Growth from 2Q02 (B) 8/1 cls Wk $ chg % chg Wkly mkt cap chg ($M) 8/1 mkt cap ($M)
Aventis (AVE) NA E0.76 NA 19% $49.39 -$4.51 -8% -$3,606 $39,487
Company does not have enough analysts reporting to

Read the full 525 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers